-- Joins Canada Equicom Group Focused on Canada --
WALTHAM, Mass., Jan. 26 /PRNewswire/ -- AltaRex Corp.
(Toronto: AXO, OTC: ALRXF) announced today that it has engaged The Trout Group
LLC, a New York and San Francisco based investor relations firm with extensive
contacts in the United States, Europe and Asia.
(Photo: http://www.newscom.com/cgi-bin/prnh/20000831/ALTREXLOGO)
The engagement of The Trout Group is in recognition of a growing base of
investors and interest in the Company in the United States. The Trout Group
will work with AltaRex to increase the Company's visibility in the United
States among key constituencies. The engagement complements the Company's
current relationship with The Equicom Group of Toronto, an investor relations
firm primarily focused on Canada.
"The Trout Group has a strong reputation bringing the potential of lesser
known biotechs with lower market caps to the attention of analysts, portfolio
managers and institutions that may not have otherwise discovered such
investments," commented AltaRex President and CEO Richard E. Bagley. "We are
very pleased to be working with The Trout Group as we enter a very exciting
year for the Company," added Mr. Bagley.
"We look forward to working with AltaRex to develop their presence in the
U.S. investor market. Our job is to help raise investor awareness of the
potential of companies like AltaRex," said Jonathan Fassberg, President of The
Trout Group.
The Trout Group provides clients a complete and fully integrated range of
financial relations services.
Among other biotechnology clients, The Trout Group provides investor
relations counsel to Biopure Corp., Cambridge Antibody Technology, Hyseq, Inc.
and Tanox, Inc.
AltaRex Corp. is focused on the research, development and
commercialization of five antigen-targeted antibodies to treat late-stage
cancers. OvaRex(R) MAb targets the tumor associated antigen CA 125 and is in
the final stages of clinical evaluation for ovarian cancer with
commercialization expected in the United States in 2002. Clinical data
reported to date, in OvaRex(R) MAb responders, evidence a prolongation in time
to relapse and/or survival in the watchful waiting and recurrent disease
indications of ovarian cancer. BrevaRex(R) MAb targets the tumor associated
antigen MUC1 and has successfully completed a Phase I safety and immunology
study. The Company will initiate a Phase I/II clinical study of BrevaRex(R)
MAb for the treatment of multiple myeloma in the second quarter of this year.
Additional information about AltaRex research and development, news and
events can be found on its web site at http://www.altarex.com. Clinical information
can also be found at http://www.centerwatch.com. Additional information about
ovarian cancer can be found at http://www.nci.nih.gov, http://www.ovariancanada.org and at
http://www.ovarian.org.
This news release contains forward-looking statements that involve risks
and uncertainties, which may cause actual results to differ materially from
the statements made. For this purpose, any statements that are contained
herein that are not statements of historical fact may be deemed to be forward-
looking statements. Without limiting the foregoing, the words "believes,"
"anticipates," "plans," "intends," "expects" and similar expressions are
intended to identify forward-looking statements. Such risks and uncertainties
include, but are not limited to uncertainty of pre-clinical, retrospective and
early clinical trial results, such as the results described above which may
not be indicative of results that will be obtained in ongoing or future
clinical trials, our need for capital and the risk that the Company cannot
raise funds on a timely basis on satisfactory terms or at all, changing market
conditions, completion of clinical trials, patient enrollment rates, the
establishment of manufacturing processes and new corporate alliances, the
timely development, regulatory approval and market acceptance of the Company's
products, uncertainty as to whether patents will issue from pending patent
applications and, if issued, as to whether such patents will be sufficiently
broad to protect the Company's technology, and other risks detailed from time-
to-time in the Company's filings with the United States Securities and
Exchange Commission and Canadian securities authorities.
THE TORONTO STOCK EXCHANGE HAS NOT APPROVED OR DISAPPROVED OF THE
INFORMATION CONTAINED HEREIN.
SOURCE AltaRex Corp.
 back to top
Related links:
http://www.altarex.com
Photo Notes:
NewsCom:
http://www.newscom.com/cgi-bin/prnh/20000831/ALTREXLOGO
AP Archive: http://photoarchive.ap.org
PRN Photo Desk, 888-776-6555 or 201-369-3467
Company News On-Call:
http://www.prnewswire.com/comp/128163.html or fax,
800-758-5804, ext. 128163
CONTACT:
Sondra Henrichon, Director, Investor
Relations and Corporate Communications of AltaRex Corp.,
781-672-0138 ext. 5110, shenrichon@altarex.com
|
